1. Home
  2. AKBA vs CARE Comparison

AKBA vs CARE Comparison

Compare AKBA & CARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • CARE
  • Stock Information
  • Founded
  • AKBA 2007
  • CARE 1974
  • Country
  • AKBA United States
  • CARE United States
  • Employees
  • AKBA N/A
  • CARE N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • CARE Major Banks
  • Sector
  • AKBA Health Care
  • CARE Finance
  • Exchange
  • AKBA Nasdaq
  • CARE Nasdaq
  • Market Cap
  • AKBA 336.2M
  • CARE 393.2M
  • IPO Year
  • AKBA 2014
  • CARE N/A
  • Fundamental
  • Price
  • AKBA $1.93
  • CARE $16.05
  • Analyst Decision
  • AKBA Strong Buy
  • CARE Buy
  • Analyst Count
  • AKBA 3
  • CARE 2
  • Target Price
  • AKBA $6.50
  • CARE $21.50
  • AVG Volume (30 Days)
  • AKBA 6.1M
  • CARE 58.2K
  • Earning Date
  • AKBA 05-08-2025
  • CARE 04-24-2025
  • Dividend Yield
  • AKBA N/A
  • CARE N/A
  • EPS Growth
  • AKBA N/A
  • CARE 6.25
  • EPS
  • AKBA N/A
  • CARE 1.06
  • Revenue
  • AKBA $160,180,000.00
  • CARE $140,871,000.00
  • Revenue This Year
  • AKBA $23.40
  • CARE $11.93
  • Revenue Next Year
  • AKBA $58.44
  • CARE $13.02
  • P/E Ratio
  • AKBA N/A
  • CARE $15.26
  • Revenue Growth
  • AKBA N/A
  • CARE 4.98
  • 52 Week Low
  • AKBA $0.80
  • CARE $10.95
  • 52 Week High
  • AKBA $2.89
  • CARE $20.40
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 46.74
  • CARE 38.13
  • Support Level
  • AKBA $1.83
  • CARE $16.56
  • Resistance Level
  • AKBA $1.99
  • CARE $16.98
  • Average True Range (ATR)
  • AKBA 0.19
  • CARE 0.40
  • MACD
  • AKBA -0.03
  • CARE -0.02
  • Stochastic Oscillator
  • AKBA 15.42
  • CARE 12.20

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About CARE Carter Bankshares Inc.

Carter Bankshares Inc is a bank holding company that conducts its business solely through the bank. The Bank earns revenue from interest on loans and securities and fees charged for financial services provided to customers. It offers a full range of deposit services including Lifetime Free Checking, interest checking accounts, savings accounts, retirement accounts and other deposit accounts of various types, ranging from money market accounts to longer-term CDs. The Bank offers a full range of commercial and consumer loans. The Bank also originates and holds fixed and variable-rate mortgage loans and offers home equity lines of credit to its customers.

Share on Social Networks: